Lodoxamide

Lodoxamide

CAT N°: 23994
Price:

From 146.00 124.10

Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a ?-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2,2′-[(2-chloro-5-cyano-1,3-phenylene)diimino]bis[2-oxo-acetic acid]
  • Correlated keywords
    • Thilomide GPR-35 CHOK1 A-23187 antiIgE g protein-coupled receptor
  • Product Overview:
    Lodoxamide is a potent agonist of GPR35 with an EC50 value of 1.61 nM in a ?-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor.{38490} It inhibits histamine release induced by compound 48/80 (Item No. 22173), anti-IgE, or A23187 (Item No. 11016) in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) and inhibits A23187-induced calcium influx in mast cells.{38491} It reduces antigen-induced histamine release from rat conjunctival tissue by 46% in vitro when used at a concentration of 10 µg/ml.{38492} Lodoxamine (0.1 and 10%, w/v) reduces the immediate hypersensitivity response in rat conjunctiva in vivo in a dose-dependent manner and reduces mast cell degranulation in a topical ovalbumin challenge.{38492,38493} Formulations containing lodoxamide have been used in the treatment of vernal conjunctivitis and keratitis.

We also advise you